Humana Q3FY26 Results: Analysts forecast $1.00 loss, revenue up 25%
Humana Inc. is set to report Q3FY26 earnings on Nov 6, with analysts forecasting a $1.00 loss per share, down from $3.24 a year ago, despite a 25% revenue increase to $40.89 billion. Several analysts raised price targets, with Raymond James initiating an Outperform rating and $520 target. The company declared a $0.885 dividend and reaffirmed FY26 adjusted EPS guidance of at least $9.00.
How this was made
The 30-second read
Why it matters
The JV may enhance long‑term profitability, but short‑term earnings pressure remains.
Market read
Upcoming earnings and analyst target revisions make Humana a near‑term trading focus.
What to watch
The new joint venture with BlackRock could improve margins and reduce liabilities, mitigating the loss impact.
Background
Humana announced a joint venture with BlackRock to replace a prior partnership, aiming to lower liabilities and cost of capital.
Ticker impact
Humana is slated to report Q3 FY26 earnings with a forecast loss of $1.00 EPS and revenue of $40.89B; analysts have raised price targets to $495‑$525.
likely pressure ahead of the release, with upside potential if results exceed the loss forecast
The consensus loss and high price targets create a mixed view; traders may short ahead of the report but could cover on a beat.
Market effects
The health‑insurance sector may see broader pressure if Humana confirms a loss, affecting peers.
U.S. markets could see modest volatility in the financials segment.
Limited; primarily U.S. health‑insurance investors are affected.
Counterpoint
If Humana can offset the loss with strong revenue growth, the stock may rally on surprise earnings.
Key entities
- companyHumana Inc.
U.S. health‑insurance provider
- companyBlackRock
Asset manager entering joint venture with Humana
